NCT01754857View on ClinicalTrials.gov

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 12, 2013

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Lymphoid LeukemiaSmall Lymphocytic LymphomaLymphoma, Non-Hodgkin
Interventions
DRUG

Bendamustine

Given IV

DRUG

Rituximab

Given IV

DRUG

Lenalidomide

Given PO

Trial Locations (1)

53792

University of Wisconsin, Madison

Sponsors
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT01754857 - Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | Biotech Hunter | Biotech Hunter